FibroGen Adrift After Yet Another Pamrevlumab Failure
Executive Summary
The asset appears to have a similar future in Duchenne muscular dystrophy as it has in idiopathic pulmonary fibrosis – to wit, none.
You may also be interested in...
FibroGen Rocked By Second Pivotal Pamrevlumab Failure – This Time In IPF
Months after a disappointment in Duchenne muscular dystrophy, the US firm’s pamrevlumab has missed the mark in a pivotal idiopathic pulmonary fibrosis trial, boding poorly for other trials and forcing the firm to enter cost-cutting mode.
FibroGen Misses In First Of Two Pivotal DMD Trials
The biotech’s pamrevlumab fails a Phase III study in non-ambulatory Duchenne muscular dystrophy, but the antibody still has a shot in ambulatory DMD, as well as IPF and pancreatic cancer.
A Look Into The Future Of NASH
The liver disease is one of the hottest areas of drug development. Here are some upcoming catalysts to look out for.